← All trials
NCT06778564
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2025
- Primary completion
- Dec 31, 2027
- Completion date
- Dec 31, 2028
- First posted
- Jan 16, 2025
- Last posted
- Jan 16, 2025
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of OxfordLead sponsor
- University of OxfordCollaborator
- Diagram B.V.Collaborator
- University of OxfordOfficial
- University of ZurichCollaborator
- Tel Aviv UniversityCollaborator
- Technion UniversityCollaborator
- University of AthensCollaborator
- Medical University of ViennaCollaborator
- Swansea UniversityCollaborator
- University of Campania Luigi VanvitelliCollaborator
- Humboldt UniversityCollaborator
- University of CambridgeCollaborator
- University of CologneCollaborator
- University of AugsburgCollaborator
- Cambridge Cognition LtdCollaborator
- Hospital General Universitario Gregorio MarañonCollaborator
- University of AmsterdamCollaborator
- University of SevilleCollaborator
- Wellcome TrustCollaborator
- MyonexCollaborator
- Ludwig Maximilians UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.